

Breast Cancer

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Trial Status
Completed

Trial Runs In
1 Countries

Trial Identifier
NCT02613208 ROC-BEV-2015-01
ML29756

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, observational, prospective study will identify a powerful and easy predictive/prognostic marker to use with participants under bevacizumab.

Hoffmann-La Roche
Sponsor

N/A
Phase

NCT02613208 ROC-BEV-2015-01 ML29756
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
